81171-71-3

Usage

Uses

Used in Pharmaceutical Research:
4-BROMO-2-FLUOROPHENYLISOTHIOCYANATE 96 is used as a reagent for introducing the isothiocyanate functional group into organic molecules, which is crucial for the development of new pharmaceutical compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 4-BROMO-2-FLUOROPHENYLISOTHIOCYANATE 96 is utilized as a key intermediate for the synthesis of various organic molecules, contributing to the advancement of chemical research and product development.
Used in Production of Pharmaceutical Intermediates:
4-BROMO-2-FLUOROPHENYLISOTHIOCYANATE 96 is used as a starting material or intermediate in the production of pharmaceutical intermediates, which are essential for the synthesis of final drug products.
Used in Agrochemicals:
4-BROMO-2-FLUOROPHENYLISOTHIOCYANATE 96 is also used in the development of agrochemicals, where it serves as a building block for creating new compounds that can be used in agriculture for pest control and crop protection.

InChI:InChI=1/C7H3BrFNS/c8-5-1-2-7(10-4-11)6(9)3-5/h1-3H

Upstream product

• 463-71-8 thiophosgene 
• 367-24-8 4-bromo-2-fluoroaniline 
• 1414781-42-2 C₇H₅BrFNS₂*C₆H₁₂N₂ 
• 75-15-0 carbon disulfide 

Downstream Products

• 791594-38-2 N-(4-bromo-2-fluorophenyl)-N-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]amine 
• 81171-70-2 4'-bromo-2'-fluoro-2-oxocyclohexane-1-thiocarboxanilide 
• 1356679-58-7 methyl 1-(4-(6-(2-ethylthiazolidine-3-carbonyl)benzo[d]thiazol-2-yl)-3-fluorobenzyl)azetidine-3-carboxylate 
• 1365917-11-8 C₂₆H₂₈FN₃O₃S₂ 
• 1365917-18-5 C₂₅H₂₆FN₃O₃S₂ 
• 1365901-84-3 C₂₃H₂₃FN₂O₃S 
• 1365902-15-3 C₂₄H₂₅FN₂O₃S 
• 1356679-34-9 C₂₄H₂₄FN₃O₃S 
• 1365902-37-9 C₂₂H₂₁FN₂O₃S 
• 1365902-57-3 C₂₁H₁₉FN₂O₃S₂ 
• 1365902-81-3 C₂₂H₂₁FN₂O₃S₂ 
• 1356679-57-6 (2-(4-(1,3-dioxan-2-yl)-2-fluorophenyl)benzo[d]thiazol-6-yl)(2-ethylthiazolidin-3-yl)methanone 
• 1365902-88-0 C₂₄H₂₅FN₂O₃S₂ 
• 1365903-06-5 C₂₃H₂₃FN₂O₃S₂ 

Relevant academic research and scientific papers

Synthetic method of isothiocyanate liquid crystal monomers

The invention discloses a synthetic method of isothiocyanate liquid crystal monomers. The synthetic method comprises the following steps: taking a halogenated aniline as a raw material, firstly preparing an active intermediate of an isothiocyanate group, reacting with different coupling substrates, and then purifying to obtain a series of isothiocyanate liquid crystal monomers. The method comprises the steps of salifying, isothiocyanic acid esterification, coupling and purification to finally obtain the product. According to the method, the reaction paths and post-treatment are optimized, andhigh yield is achieved while the product purity is guaranteed.

GLP-1R AGONISTS AND USES THEREOF

Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

NOVEL BENZIMIDAZOLE BASED EGFR INHIBITORS

The present invention disclosed a novel EGFR inhibitor compound of formula (I), process for preparation thereof and methods of treating abnormal cell growth in mammals by administering the compounds of formula (I). Wherein, R= -H, 3-CH3, 4-NO2, 4-Cl, 2-CH3, 4-CH3, 4-Br, 4-F R1= -H, -4-OCH3, -4-NO2,-2-NO2, -4-Cl, -2,4,6-CH3, -4-CH3, -2-F,4-Br, -4-CF3, -4-S-CH3, -4-Cl,-3-CF3, -3-S-CH3, -3,5-CF3, -2-S-CH3, -3-CF3,-4-OCF3, -Si-(CH3)3, -Si-(C2H5)3, (CH3)2-Si- C2H5.

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

This paper describe the structural optimization of a hit compound, N 2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine- 2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N 8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.

Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: Potent S1P1 agonists with in vivo lymphocyte-depleting activity

An SAR campaign designed to increase polarity in the 'tail' region of benzothiazole 1 resulted in two series of structurally novel 5-and 6-substituted S1P1 agonists. Structural optimization for potency ultimately delivered carboxamide (+)-11f,